R

REGENXBIO

Develops AAV gene delivery therapies

Lead Integration Developer

Backend EngineeringConfirmed live in the last 24 hours
Full-timeRockville, MD, USA

About the Job

Requirements

  • A Bachelor of Science in Computer Science, CIS, Math, or Science, or equivalent, is required.
  • At least 10 years of development or programming experience in Java, C, C#, or another traditional programming language, including three to five years as a lead, is required.
  • Basic proficiency in JavaScript is required for Oracle Integration Cloud and internal application support.
  • At least three years of experience integrating systems in a biotech environment is required.
  • Ability to create data pipelines in Azure cloud is required.
  • At least three years of experience designing integrations in Oracle Integration Cloud or similar iPaaS or SOA platforms is required.
  • At least three years of experience developing and interfacing with various API technologies is required.
  • Experience with authentication and security protocols such as OAuth 2.0, JWT, and API keys is required.
  • Deep knowledge of databases, particularly Oracle and SQL Server, with some proficiency in ANSI SQL, is required; NoSQL experience is a plus.
  • A strong understanding of ERP systems, particularly supply chain execution, and integration through web services using Oracle Integration Cloud middleware is required.
  • Web development experience in Java, servlet technology, PHP, or another technology, and knowledge of JavaScript, is a plus.
  • Outstanding interpersonal skills, a team-player attitude, clear written and verbal communication skills, and keen attention to detail are expected.
  • Ability to work effectively in a high-demand, fast-paced, evolving environment, and to work on and manage multiple projects at a time, is required.

Responsibilities

  • Design and orchestrate workflows and integrations in Oracle Integration Cloud.
  • Design, code, unit test, and maintain integration solutions using custom-built API endpoints and interfacing with external third-party APIs using REST, SOAP, and GraphQL.
  • Design, develop, unit test, and maintain custom in-house applications in Java, C, C# (.NET), or other traditional programming languages.
  • Assist the Data Architect in designing, developing, architecting, and maintaining databases, particularly in Oracle and SQL Server, and other cloud databases.
  • Design and develop smaller-scale web applications for in-house use.
  • Collaborate with the team and business stakeholders to gather requirements, design systems, and demonstrate and review written code.
  • Lead and coach junior team members in designing, developing, and coding, and delegate tasks to team members for execution.
  • Document designs and code; adhere to change management and validation processes; use source code control repositories such as Git; conduct code reviews; implement continuous integration; and design with ongoing attention to security and protecting applications from threats.
  • Assist in maintaining websites in Azure DevOps and in the code review process.

Desired Qualifications

  • Knowledge of agile practices through Kanban and/or Scrum is desirable.
  • NoSQL experience is a plus.
  • Web development experience in Java, servlet technology, PHP, or another technology, and knowledge of JavaScript, is a plus.

About the Company

REGENXBIO

Develops AAV gene delivery therapies

REGENXBIO focuses on gene therapy using its NAV Technology Platform, an adeno-associated virus (AAV) gene delivery system with exclusive rights to more than 100 AAV vectors. The company generates revenue by licensing its platform, collecting royalties, and engaging in collaborations, while also developing its own one-time gene therapies for retinal, rare, and neurodegenerative diseases. Key products in later-stage trials include ABBV-RGX-314 for wet AMD and diabetic retinopathy, RGX-202 for Duchenne muscular dystrophy, and RGX-121 for Hunter syndrome, with a goal to advance five new therapies to pivotal-stage or commercial status by 2025 and FDA review for RGX-121 targeted in early 2026. REGENXBIO differentiates itself by owning a broad AAV vector library and offering end-to-end capabilities—from research to manufacturing—alongside a diversified revenue model that includes royalties, collaborations, and milestones.

Company size
201-500
Company stage
IPO
Headquarters
Rockville, MD
Founded
2009

Recently Posted Jobs

Explore more opportunities at REGENXBIO

See more jobs